ALXN1840
ALXN1840-WD-302
Phase 3 small_molecule terminated
Quick answer
ALXN1840 for Wilson Disease is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Wilson Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated